CEO on Recent News A recent study found that Chronic Kidney Disease affects “as many as 40% of the elderly population in Canada and other developed countries” = a large addressable market for AGN.c AGNPF who were granted a patent in Japan for treating CKD with drug NP-251 or Repirinast.
Repirinast highlights
- Has data showing it reduced fibrosis by 51%
- Showed an additive benefit to medicine blood pressure drug telmisartan in a mouse model
If AGN can continue testing Repirinast and prove it’s effective against CKD the opportunity for them is huge. Especially considering they are sitting with a $2.27M MC.
CEO discusses more about the method of use patent in this interview.
https://www.youtube.com/watch?v=H04k_Ek6gPI